Celgene's Otezla to treat psoriasis does not make it to NICE list of final drug recommendations

26 November 2015

US biotech firm Celgene Corp’s (Nasdaq: CELG) Otezla (apremilast) to treat chronic plaque psoriasis, has been dropped from the list of recommendations by the National Institute for Health and Care Excellence (NICE).

The latest round of recommendations saw the regulator recommend Vortioxetine for the treatment of depression.

The drug is marketed under the brand name Brintellix by Danish CNS specialist Lundbeck (LUN: CO) and Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK